Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (934) 934
index medicus (922) 922
myeloablative agonists - therapeutic use (726) 726
male (674) 674
female (670) 670
hematology (659) 659
transplantation (623) 623
adult (541) 541
middle aged (525) 525
immunology (460) 460
transplantation conditioning - methods (417) 417
transplantation, homologous (396) 396
adolescent (376) 376
bone-marrow-transplantation (331) 331
hematopoietic stem cells (331) 331
hematopoietic stem cell transplantation (321) 321
stem cells (321) 321
hematology, oncology and palliative medicine (309) 309
treatment outcome (305) 305
aged (304) 304
survival analysis (280) 280
child (261) 261
oncology (257) 257
retrospective studies (256) 256
transplantation conditioning (231) 231
child, preschool (211) 211
versus-host-disease (204) 204
hematopoietic stem cell transplantation - methods (202) 202
stem-cell transplantation (184) 184
myeloablative agonists - administration & dosage (175) 175
graft vs host disease - prevention & control (174) 174
vidarabine - analogs & derivatives (170) 170
recurrence (166) 166
young adult (165) 165
hematopoietic stem cell transplantation - adverse effects (164) 164
analysis (160) 160
chemotherapy (160) 160
hematologic neoplasms - therapy (158) 158
myeloablative agonists - adverse effects (151) 151
infant (149) 149
unrelated donors (147) 147
graft vs host disease - mortality (143) 143
health aspects (142) 142
care and treatment (139) 139
bone marrow (138) 138
mortality (136) 136
cancer (135) 135
disease-free survival (133) 133
transplantation, autologous (133) 133
graft vs host disease - immunology (130) 130
leukemia (125) 125
article (120) 120
vidarabine - therapeutic use (120) 120
immunosuppressive agents - therapeutic use (117) 117
risk factors (116) 116
transplantation conditioning - adverse effects (114) 114
prognosis (112) 112
stem cell transplantation (110) 110
acute myeloid-leukemia (109) 109
graft vs host disease - pathology (107) 107
busulfan - therapeutic use (104) 104
melphalan - therapeutic use (103) 103
therapy (103) 103
children (102) 102
cyclophosphamide (101) 101
leukemia, myeloid, acute - therapy (100) 100
hematologic neoplasms - immunology (98) 98
busulfan (96) 96
cyclophosphamide - therapeutic use (96) 96
follow-up studies (95) 95
hematologic neoplasms - mortality (95) 95
busulfan - administration & dosage (93) 93
histocompatibility testing (93) 93
graft vs host disease - etiology (91) 91
prospective studies (88) 88
fludarabine (87) 87
survival (85) 85
survival rate (84) 84
remission induction (83) 83
research (83) 83
antineoplastic combined chemotherapy protocols - therapeutic use (82) 82
acute disease (81) 81
hematologic neoplasms - pathology (79) 79
siblings (79) 79
combined modality therapy (75) 75
risk (74) 74
time factors (74) 74
total-body irradiation (74) 74
graft survival (72) 72
pediatrics (72) 72
patient outcomes (69) 69
hematopoietic stem cell transplantation - mortality (67) 67
whole-body irradiation (66) 66
hematologic malignancies (65) 65
leukemia, myeloid, acute - mortality (65) 65
multiple myeloma - therapy (65) 65
abridged index medicus (64) 64
bone marrow transplantation (64) 64
dosage and administration (63) 63
t cells (61) 61
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (941) 941
French (5) 5
Spanish (3) 3
Russian (2) 2
Chinese (1) 1
Czech (1) 1
Danish (1) 1
German (1) 1
Hungarian (1) 1
Japanese (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning
by Kanakry, Christopher G and O'Donnell, Paul V and Furlong, Terry and De Lima, Marcos J and Wei, Wei and Medeot, Marta and Mielcarek, Marco and Champlin, Richard E and Jones, Richard J and Thall, Peter F and Andersson, Borje S and Luznik, Leo
Journal of Clinical Oncology, ISSN 0732-183X, 11/2014, Volume 32, Issue 31, pp. 3497 - 3505
Purpose The clinical safety and efficacy of intravenous busulfan and fludarabine (IV Bu/Flu) myeloablative conditioning as well as graft-versus-host disease... 
PLUS CYCLOPHOSPHAMIDE | RESPONSE CRITERIA | ONCOLOGY | MATCHED UNRELATED DONORS | VENOOCCLUSIVE DISEASE | DAILY INTRAVENOUS BUSULFAN | PERIPHERAL-BLOOD | ACUTE MYELOID-LEUKEMIA | STEM-CELL TRANSPLANTATION | HEMATOLOGIC MALIGNANCIES | INTERNATIONAL WORKING GROUP | Myeloablative Agonists - therapeutic use | Graft vs Host Disease - epidemiology | Busulfan - therapeutic use | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Hematopoietic Stem Cell Transplantation | Male | Treatment Outcome | Vidarabine - analogs & derivatives | Vidarabine - therapeutic use | Cyclophosphamide - therapeutic use | Incidence | Bayes Theorem | Adult | Female | Graft vs Host Disease - prevention & control | Aged | Transplantation Conditioning - methods | Index Medicus | ORIGINAL REPORTS | Bone1
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: Long-term results in a series of 421 patients
by Cibeira, Maria Teresa and Sanchorawala, Vaishali and Seldin, David C and Quillen, Karen and Berk, John L and Dember, Laura M and Segal, Adam and Ruberg, Frederick and Meier-Ewert, Hans and Andrea, Nancy T and Sloan, J. Mark and Finn, Kathleen T and Doros, Gheorghe and Blade, Joan and Skinner, Martha
Blood, ISSN 0006-4971, 10/2011, Volume 118, Issue 16, pp. 4346 - 4352
Previous studies have suggested that, in patients with AL amyloidosis treated with high-dose melphalan and autologous stem-cell transplantation (HDM/SCT), the... 
MULTIPLE-MYELOMA | SURVIVAL | PREDNISONE | LIGHT-CHAIN AMYLOIDOSIS | PLUS DEXAMETHASONE | PRIMARY SYSTEMIC AMYLOIDOSIS | RANDOMIZED-TRIAL | BORTEZOMIB | HEMATOLOGY | CHEMOTHERAPY | BLOOD | Myeloablative Agonists - therapeutic use | Amyloidosis - therapy | Humans | Middle Aged | Hematopoietic Stem Cell Transplantation | Male | Transplantation, Autologous | Treatment Outcome | Amyloidosis - drug therapy | Hematologic Tests | Antineoplastic Agents, Alkylating - administration & dosage | Melphalan - therapeutic use | Immunoglobulin Light Chains - metabolism | Antineoplastic Agents, Alkylating - therapeutic use | Disease-Free Survival | Melphalan - administration & dosage | Aged, 80 and over | Myeloablative Agonists - administration & dosage | Adult | Female | Aged | Amyloidosis - metabolism | Index Medicus | Abridged Index Medicus | Lymphoid Neoplasia | Clinical Trials and Observations | Transplantation
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Allogeneic hematopoietic stem cell transplantation in thalassemia major: Results of a reduced-toxicity conditioning regimen based on the use of treosulfan
by Bernardo, Maria Ester and Piras, Eugenia and Vacca, Adriana and Giorgiani, Giovanna and Zecca, Marco and Bertaina, Alice and Pagliara, Daria and Contoli, Benedetta and Pinto, Rita Maria and Caocci, Giovanni and Mastronuzzi, Angela and La Nasa, Giorgio and Locatelli, Franco
Blood, ISSN 0006-4971, 07/2012, Volume 120, Issue 2, pp. 473 - 476
Sixty thalassemia patients (median age, 7 years; range, 1-37) underwent allogeneic hematopoietic stem cell transplantation (HSCT) after a preparation combining... 
HEMATOLOGY | FLUDARABINE | BONE-MARROW-TRANSPLANTATION | DISEASE | Myeloablative Agonists - therapeutic use | Thiotepa - therapeutic use | Busulfan - analogs & derivatives | Humans | Child, Preschool | Infant | Male | Hematopoietic Stem Cell Transplantation - mortality | Transplantation, Homologous | Young Adult | Hematopoietic Stem Cell Transplantation - adverse effects | Adult | Female | Transplantation Conditioning - methods | Child | Graft vs Host Disease - etiology | beta-Thalassemia - therapy | Busulfan - therapeutic use | Risk Factors | Treatment Outcome | Vidarabine - analogs & derivatives | Vidarabine - therapeutic use | Adolescent | Hematopoietic Stem Cell Transplantation - methods | Cohort Studies | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: A center for international blood and marrow transplant research study
by D'Souza, Anita and Dispenzieri, Angela and Wirk, Baldeep and Zhang, Mei-Jie and Huang, Jiaxing and Gertz, Morie A and Kyle, Robert A and Kumar, Shaji and Comenzo, Raymond L and Gale, Robert Peter and Lazarus, Hillard M and Savani, Bipin N and Cornell, Robert F and Weiss, Brendan M and Vogl, Dan T and Freytes, César O and Scott, Emma C and Landau, Heather J and Moreb, Jan S and Costa, Luciano J and Ramanathan, Muthalagu and Callander, Natalie S and Kamble, Rammurti T and Olsson, Richard F and Ganguly, Siddhartha and Nishihori, Taiga and Kindwall-Keller, Tamila L and Wood, William A and Mark, Tomer M and Hari, Parameswaran and Medicinska och farmaceutiska vetenskapsområdet and Uppsala universitet and Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm and Centrum för klinisk forskning i Sörmland (CKFD)
Journal of Clinical Oncology, ISSN 0732-183X, 11/2015, Volume 33, Issue 32, pp. 3741 - 3749
Purpose Autologous hematopoietic cell transplantation, or autotransplantation, is effective in light-chain amyloidosis (AL), but it is associated with a high... 
MULTIPLE-MYELOMA | STAGING SYSTEM | SURVIVAL | DEXAMETHASONE | ONCOLOGY | CYCLOPHOSPHAMIDE | PRIMARY SYSTEMIC AMYLOIDOSIS | HIGH-DOSE MELPHALAN | BORTEZOMIB | AL AMYLOIDOSIS | CARDIAC BIOMARKERS | Myeloablative Agonists - therapeutic use | Humans | Middle Aged | Kaplan-Meier Estimate | Amyloidosis - mortality | Hematopoietic Stem Cell Transplantation | Male | Transplantation, Autologous | Treatment Outcome | Amyloidosis - drug therapy | Melphalan - therapeutic use | Disease Progression | Antineoplastic Agents, Alkylating - therapeutic use | Disease-Free Survival | Immunoglobulin Light Chains | Amyloidosis - surgery | Karnofsky Performance Status | Amyloidosis - immunology | Adult | Female | Aged | Retrospective Studies | Databases, Factual | Index Medicus | ORIGINAL REPORTS | Bone5 | Clinical Medicine | Medical and Health Sciences | Cancer and Oncology | Klinisk medicin | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation
by Kroger, N and Holler, E and Kobbe, G and Bornhauser, M and Schwerdtfeger, R and Baurmann, H and Nagler, A and Bethge, W and Stelljes, M and Uharek, L and Wandt, H and Burchert, A and Corradini, P and Schubert, J and Kaufmann, Martin and ger, P and Wulf, G.G and Einsele, H and Zabelina, T and Kvasnicka, H.M and Thiele, J and Brand, R and Zander, A.R and Niederwieser, D and Witte, T.J.M. de
Blood, ISSN 0006-4971, 2009, Volume 114, Issue 26, pp. 5264 - 5270
From 2002 to 2007, 103 patients with primary myelofibrosis or postessential thrombocythemia and polycythemia vera myelofibrosis and a median age of 55 years... 
DONOR-LYMPHOCYTE INFUSION | MYELOPROLIFERATIVE DISORDERS | PROGNOSTIC-FACTORS | IDIOPATHIC MYELOFIBROSIS | GRUPPO-ITALIANO | MUTATION | AGNOGENIC MYELOID METAPLASIA | GRAFT | ESSENTIAL THROMBOCYTHEMIA | HEMATOLOGY | MIDOLLO-OSSEO | Myeloablative Agonists - therapeutic use | Primary Myelofibrosis - mortality | Recurrence | Graft vs Host Disease - epidemiology | Busulfan - therapeutic use | Humans | Middle Aged | Male | Vidarabine - analogs & derivatives | Primary Myelofibrosis - surgery | Vidarabine - therapeutic use | Transplantation, Homologous | Disease-Free Survival | Stem Cell Transplantation - methods | Adult | Female | Aged | Transplantation Conditioning - methods | Stem Cell Transplantation - adverse effects | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma
by Giralt, Sergio and Garderet, Laurent and Durie, Brian and Cook, Gordon and Gahrton, Gosta and Bruno, Benedetto and Hari, Paremesweran and Lokhorst, Henk and McCarthy, Phillip and Krishnan, Amrita and Sonneveld, Pieter and Goldschmidt, Harmut and Jagannath, Sundar and Barlogie, Bart and Mateos, Maria and Gimsing, Peter and Sezer, Orhan and Mikhael, Joseph and Lu, Jin and Dimopoulos, Meletios and Mazumder, Amitabha and Palumbo, Antonio and Abonour, Rafat and Anderson, Kenneth and Attal, Michel and Blade, Joan and Bird, Jenny and Cavo, Michele and Comenzo, Raymond and de la Rubia, Javier and Einsele, Hermann and Garcia-Sanz, Ramon and Hillengass, Jens and Holstein, Sarah and Johnsen, Hans Erik and Joshua, Douglas and Koehne, Guenther and Kumar, Shaji and Kyle, Robert and Leleu, Xavier and Lonial, Sagar and Ludwig, Heinz and Nahi, Hareth and Nooka, Anil and Orlowski, Robert and Rajkumar, Vincent and Reiman, Anthony and Richardson, Paul and Riva, Eloisa and San Miguel, Jesus and Turreson, Ingemar and Usmani, Saad and Vesole, David and Bensinger, William and Qazilbash, Muzaffer and Efebera, Yvonne and Mohty, Mohamed and Gasparreto, Christina and Gajewski, James and LeMaistre, Charles F and Bredeson, Chris and Moreau, Phillipe and Pasquini, Marcelo and Kroeger, Nicolaus and Stadtmauer, Edward and Division of Hematology and Transfusion Medicine and Lund University and Lunds universitet and Avdelningen för hematologi och transfusionsmedicin
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2015, Volume 21, Issue 12, pp. 2039 - 2051
Abstract In contrast to the upfront setting in which the role of high-dose therapy with autologous hematopoietic cell transplantation (HCT) as consolidation of... 
Hematology, Oncology and Palliative Medicine | Stem cell transplantation | Myeloma | Salvage therapy | BORTEZOMIB-THALIDOMIDE-DEXAMETHASONE | COMBINATION THERAPY | LENALIDOMIDE PLUS DEXAMETHASONE | AUTOLOGOUS TRANSPLANTATION | FOLLOW-UP | RISK | IMMUNOLOGY | TRANSPLANTATION | ALLOGENEIC TRANSPLANTATION | MAINTENANCE | RANDOMIZED PHASE-III | HEMATOLOGY | LOW-DOSE DEXAMETHASONE | Myeloablative Agonists - therapeutic use | Recurrence | Humans | Antibodies, Monoclonal - therapeutic use | Multiple Myeloma - immunology | Transplantation, Autologous | Bone Marrow Transplantation - methods | Remission Induction | Proteasome Inhibitors - therapeutic use | Transplantation, Homologous | Randomized Controlled Trials as Topic | Multiple Myeloma - pathology | Multiple Myeloma - therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Hematopoietic Stem Cell Transplantation - methods | Transplantation Conditioning - methods | Salvage Therapy - methods | Immunologic Factors - therapeutic use | Relapse | Multiple myeloma | Bone marrow | Clinical trials | Transplantation | Conferences and conventions | Hematopoietic stem cells | Trade and professional associations | Diseases | Index Medicus | Clinical Medicine | Hematologi | Medical and Health Sciences | Hematology | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Randomized Trial of Myeloablative Conditioning Regimens: Busulfan Plus Cyclophosphamide Versus Busulfan Plus Fludarabine
by Je-Hwan Lee and Young-Don Joo and Hawk Kim and Hun Mo Ryoo and Min Kyoung Kim and Gyeong-Won Lee and Jung-Hee Lee and Won-Sik Lee and Jae-Hoo Park and Sung-Hwa Bae and Myung Soo Hyun and Dae-Young Kim and Sung-Doo Kim and Young Joo Min and Kyoo-Hyung Lee
Journal of Clinical Oncology, ISSN 0732-183X, 02/2013, Volume 31, Issue 6, pp. 701 - 709
Purpose We conducted a phase III randomized clinical trial to compare two myeloablative conditioning regimens for allogeneic hematopoietic cell transplantation... 
TOTAL-BODY IRRADIATION | HLA-MISMATCHED MARROW | ONCOLOGY | HEPATIC VENOOCCLUSIVE DISEASE | DAILY IV-BUSULFAN | BONE-MARROW-TRANSPLANTATION | HIGH-RISK | DAILY INTRAVENOUS BUSULFAN | ACUTE MYELOID-LEUKEMIA | STEM-CELL TRANSPLANTATION | VERSUS-HOST-DISEASE | Myeloablative Agonists - therapeutic use | Multivariate Analysis | Myeloablative Agonists - adverse effects | Humans | Middle Aged | Male | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Transplantation, Homologous | Young Adult | Myelodysplastic Syndromes - therapy | Hematopoietic Stem Cell Transplantation - adverse effects | Adult | Female | Transplantation Conditioning - methods | Drug Therapy, Combination | Graft vs Host Disease - etiology | Busulfan - adverse effects | Busulfan - therapeutic use | Vidarabine - adverse effects | Leukemia - therapy | Treatment Outcome | Vidarabine - analogs & derivatives | Vidarabine - therapeutic use | Gastroenteritis - etiology | Adolescent | Survival Analysis | Aged | Hematopoietic Stem Cell Transplantation - methods | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Unmanipulated Haploidentical Transplants Compared with Other Alternative Donors and Matched Sibling Grafts
by Raiola, Anna Maria and Dominietto, Alida and di Grazia, Carmen and Lamparelli, Teresa and Gualandi, Francesca and Ibatici, Adalberto and Bregante, Stefania and Van Lint, Maria Teresa and Varaldo, Riccardo and Ghiso, Anna and Gobbi, Marco and Carella, Angelo Michele and Signori, Alessio and Galaverna, Federica and Bacigalupo, Andrea
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2014, Volume 20, Issue 10, pp. 1573 - 1579
Abstract We studied 459 consecutive patients with hematologic malignancies, median age 44 years (range, 15 to 71 years), who underwent transplantation with... 
Hematology, Oncology and Palliative Medicine | Unrelated | Allogeneic transplant | Cord blood | Haploidentical | BONE-MARROW-TRANSPLANTATION | ADULTS | RISK | IMMUNOLOGY | TRANSPLANTATION | ACUTE-LEUKEMIA | POSTTRANSPLANTATION CYCLOPHOSPHAMIDE | UMBILICAL-CORD BLOOD | OUTCOMES | STEM-CELL TRANSPLANTATION | HEMATOLOGY | HEMATOLOGIC MALIGNANCIES | HEMATOPOIETIC TRANSPLANTATION | Haplotypes | Hematologic Neoplasms - therapy | Myeloablative Agonists - therapeutic use | Recurrence | Prospective Studies | Hematologic Neoplasms - mortality | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Male | HLA Antigens - genetics | Transplantation, Homologous | Adult | Female | Unrelated Donors | Transplantation Conditioning - methods | Siblings | Gene Expression | Histocompatibility Testing | HLA Antigens - immunology | Hematopoietic Stem Cell Transplantation | Cord Blood Stem Cell Transplantation | Adolescent | Survival Analysis | Graft vs Host Disease - prevention & control | Aged | Hematologic Neoplasms - genetics | Hematologic Neoplasms - immunology | Methotrexate | Comparative analysis | Mortality | Leukemia | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Impact of Conditioning Regimen on Outcomes for Patients with Lymphoma Undergoing High-Dose Therapy with Autologous Hematopoietic Cell Transplantation
by Chen, Yi-Bin and Lane, Andrew A and Logan, Brent R and Zhu, Xiaochun and Akpek, Görgün and Aljurf, Mahmoud D and Artz, Andrew S and Bredeson, Christopher N and Cooke, Kenneth R and Ho, Vincent T and Lazarus, Hillard M and Olsson, Richard F and Saber, Wael and McCarthy, Philip L and Pasquini, Marcelo C
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2015, Volume 21, Issue 6, pp. 1046 - 1053
Abstract There are limited data to guide the choice of high-dose therapy (HDT) regimen before autologous hematopoietic cell transplantation (AHCT) for patients... 
Hematology, Oncology and Palliative Medicine | Idiopathic pneumonia syndrome | Autologous transplantation | Lymphoma | RISK-FACTORS | PROGNOSTIC-FACTORS | SPANISH COOPERATIVE GROUP | CYCLOPHOSPHAMIDE | BONE-MARROW-TRANSPLANTATION | Idiopathic pneumonia | PREPARATIVE REGIMENS | IMMUNOLOGY | CHEMOTHERAPY | TRANSPLANTATION | ETOPOSIDE | syndrome | DISEASE | NON-HODGKINS-LYMPHOMA | HEMATOLOGY | Myeloablative Agonists - therapeutic use | Lymphoma, Non-Hodgkin - immunology | Whole-Body Irradiation | Cytarabine - therapeutic use | Hodgkin Disease - pathology | Humans | Middle Aged | Male | Transplantation, Autologous | Melphalan - therapeutic use | Cyclophosphamide - therapeutic use | Lymphoma, Non-Hodgkin - pathology | Carmustine - therapeutic use | Aged, 80 and over | Hodgkin Disease - mortality | Adult | Female | Registries | Retrospective Studies | Transplantation Conditioning - methods | Busulfan - therapeutic use | Drug Administration Schedule | Hematopoietic Stem Cell Transplantation | Etoposide - therapeutic use | Lymphoma, Non-Hodgkin - therapy | Hodgkin Disease - therapy | Adolescent | Survival Analysis | Hodgkin Disease - immunology | Aged | Lymphoma, Non-Hodgkin - mortality | Care and treatment | Patient outcomes | Analysis | Mortality | Lymphomas | Transplantation | Hematopoietic stem cells | Index Medicus | idiopathic pneumonia syndrome | autologous transplant | lymphoma
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
by Nathalie Cartier and Salima Hacein-Bey-Abina and Cynthia C. Bartholomae and Gabor Veres and Manfred Schmidt and Ina Kutschera and Michel Vidaud and Ulrich Abel and Liliane Dal-Cortivo and Laure Caccavelli and Nizar Mahlaoui and Véronique Kiermer and Denice Mittelstaedt and Céline Bellesme and Najiba Lahlou and François Lefrère and Stéphane Blanche and Muriel Audit and Emmanuel Payen and Philippe Leboulch and Bruno L'Homme and Pierre Bougnères and Christof Von Kalle and Alain Fischer and Marina Cavazzana-Calvo and Patrick Aubourg
Science, ISSN 0036-8075, 11/2009, Volume 326, Issue 5954, pp. 818 - 823
X-linked adrenoleukodystrophy (ALD) is a severe brain demyelinating disease in boys that is caused by a deficiency in ALD protein, an adenosine... 
Myeloid cells | Genetic vectors | Demyelinating diseases | B lymphocytes | Stem cells | Hematocrit | Cell lines | Gene therapy | Cells | Hematopoietic stem cells | Research Article | HIV VECTORS | SEVERE COMBINED IMMUNODEFICIENCY | INTEGRATION SITE SELECTION | MICROGLIA | BONE-MARROW-TRANSPLANTATION | HUMAN CD34(+) CELLS | MULTIDISCIPLINARY SCIENCES | MOUSE MODEL | NOD/SCID MICE | LONG-TERM ENGRAFTMENT | DIFFERENTIATE | Myeloablative Agonists - therapeutic use | Genetic Therapy | Leukocytes, Mononuclear - metabolism | Microglia - metabolism | Humans | Adrenoleukodystrophy - pathology | Male | Transplantation, Autologous | ATP-Binding Cassette Transporters - genetics | Hematopoiesis | Adrenoleukodystrophy - therapy | Hematopoietic Stem Cells - physiology | Female | Cell Differentiation | Fatty Acids - blood | Hematopoietic Stem Cells - virology | Child | Microglia - cytology | Gene Expression | Transduction, Genetic | Hematopoietic Stem Cell Transplantation | ATP Binding Cassette Transporter, Sub-Family D, Member 1 | HIV-1 - genetics | Virus Integration | Disease Progression | Cell Lineage | Animals | Brain - pathology | Mice | Adrenoleukodystrophy - genetics | Transplantation Conditioning | Genetic Vectors | Usage | Care and treatment | Adrenoleukodystrophy | Patient outcomes | Transplantation | Health aspects | Viruses | Genetic disorders | Neurological disorders | ABCD1 protein | Index Medicus | Life Sciences | Cellular Biology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Total Body Irradiation–Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors
by Solomon, Scott R and Sizemore, Connie A and Sanacore, Melissa and Zhang, Xu and Brown, Stacey and Holland, H. Kent and Morris, Lawrence E and Bashey, Asad
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2015, Volume 21, Issue 7, pp. 1299 - 1307
Abstract We enrolled 30 patients on a prospective phase II trial utilizing a total body irradiation (TBI)–based myeloablative preparative regimen (fludarabine... 
Hematology, Oncology and Palliative Medicine | Stem cell transplantation | Myeloablative | Total body irradiation | Haploidentical | Peripheral blood stem cells | HEMORRHAGIC CYSTITIS | BONE-MARROW-TRANSPLANTATION | IMMUNOLOGY | 2-STEP APPROACH | VERSUS-HOST-DISEASE | CONDITIONING REGIMEN | TRANSPLANTATION | REDUCED-INTENSITY | EUROPEAN-GROUP | HIGH-RISK | LEUKEMIA WORKING PARTY | HEMATOLOGY | HEMATOLOGIC MALIGNANCIES | Haplotypes | Hematologic Neoplasms - therapy | Myeloablative Agonists - therapeutic use | Recurrence | Whole-Body Irradiation | Prospective Studies | Hematologic Neoplasms - mortality | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Male | Risk | Hematologic Neoplasms - pathology | Graft vs Host Disease - immunology | Cyclophosphamide - therapeutic use | Graft vs Host Disease - mortality | Hematopoietic Stem Cell Transplantation - adverse effects | Adult | Female | Unrelated Donors | Graft vs Host Disease - etiology | Acute Disease | Histocompatibility Testing | Transplantation, Isogeneic | Tacrolimus - therapeutic use | Mycophenolic Acid - analogs & derivatives | Mycophenolic Acid - therapeutic use | Survival Analysis | Graft vs Host Disease - prevention & control | Hematologic Neoplasms - immunology | Hematopoietic Stem Cell Transplantation - methods | Transplantation Conditioning | Chronic Disease | Leukemia | Immunotherapy | Mortality | Stem cells | Transplantation | Lymphomas | Mycophenolate mofetil | T cells | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning
by Boelens, Jaap Jan and Boelens, Jaap Jan and Aldenhoven, Mieke and Aldenhoven, Mieke and Purtill, Duncan and Purtill, Duncan and Ruggeri, Annalisa and Ruggeri, Annalisa and Defor, Todd and DeFor, Todd and Wynn, Robert and Wynn, Robert and Wraith, E and Wraith, Ed and Cavazzana-Calvo, Marina and Cavazzana-Calvo, Marina and Rovelli, Attilio and Rovelli, Attilio and Fischer, Alain and Fischer, Alain and Tolar, Jakub and Tolar, Jakub and Prasad, Vinod K and Prasad, Vinod K and Escolar, Maria and Escolar, Maria and Gluckman, Eliane and Gluckman, Eliane and O'Meara, Anne and O’Meara, Anne and Orchard, Paul J and Orchard, Paul J and Veys, Paul and Veys, Paul and Eapen, Mary and Eapen, Mary and Kurtzberg, Joanne and Kurtzberg, Joanne and Rocha, Vanderson and Rocha, Vanderson and Eurocord, Eurocord and Malech, H and Horwitz, E and Inborn Errors Working Party of European Blood and Marrow Transplant group, Errors Working Party of European Blood and Marrow Transplant group and Le-Rademacher, J and Duke University Blood and Marrow Transplantation Program, University Blood and Marrow Transplantation Program and He, W and Centre for International Blood and Marrow Research, for International Blood and Marrow Research and Gaspar, B and Porta, F and Driscoll, T.A and Landi, D.B and Martin, P.L and Page, K.M and Parikh, H and Ctr Int Blood Marrow Res and Duke Univ and Inborn Errors Working Party of European Blood and Marrow Transplant group and Duke University Blood and Marrow Transplantation Program and Eurocord and Centre for International Blood and Marrow Research and on behalf of all participating centers from Eurocord, Inborn Errors Working Party of European Blood and Marrow Transplant group, Duke University, and the Centre for International Blood and Marrow Research
Blood, ISSN 0006-4971, 05/2013, Volume 121, Issue 19, pp. 3981 - 3987
We report transplantation outcomes of 258 children with Hurler syndrome (HS) after a myeloablative conditioning regimen from 1995 to 2007. Median age at... 
ENZYME-REPLACEMENT THERAPY | CORD BLOOD TRANSPLANTATION | BONE-MARROW-TRANSPLANTATION | PEDIATRIC-PATIENTS | DISEASE | GRAFT | DONORS | COMBINATION | HEMATOLOGY | RISK-FACTOR ANALYSIS | FAILURE | Myeloablative Agonists - therapeutic use | Myeloablative Agonists - adverse effects | Histocompatibility Testing | Humans | Child, Preschool | Mucopolysaccharidosis I - epidemiology | Infant | Male | Treatment Outcome | Young Adult | Mucopolysaccharidosis I - mortality | Hematopoietic Stem Cells - cytology | Mucopolysaccharidosis I - therapy | Tissue and Organ Procurement - methods | Adolescent | Hematopoietic Stem Cell Transplantation - adverse effects | Female | Transplantation Conditioning - adverse effects | Retrospective Studies | Hematopoietic Stem Cell Transplantation - methods | Tissue Donors | Transplantation Conditioning - methods | Child | Index Medicus | Abridged Index Medicus | Transplantation
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights